Status:
COMPLETED
Continued Access to RXDX-105
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Non Small Cell Lung Cancer
Ovarian Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
Eligibility Criteria
Inclusion
- This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):
Exclusion
- Any patients other than those described above are excluded.
Key Trial Info
Start Date :
December 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03784378
Start Date
December 14 2018
End Date
September 30 2020
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center 1275 York Avenue
New York, New York, United States, 10065